Neos Therapeutics Inc (NASDAQ:NEOS) CEO Gerald W. Mclaughlin acquired 7,403 shares of Neos Therapeutics stock in a transaction on Tuesday, December 4th. The shares were bought at an average price of $2.04 per share, with a total value of $15,102.12. Following the purchase, the chief executive officer now directly owns 7,403 shares in the company, valued at approximately $15,102.12. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.
Shares of Neos Therapeutics stock traded down $0.03 on Friday, hitting $2.00. The company’s stock had a trading volume of 449,956 shares, compared to its average volume of 539,411. Neos Therapeutics Inc has a 1 year low of $1.65 and a 1 year high of $11.69. The firm has a market cap of $60.24 million, a PE ratio of -0.75 and a beta of 0.34.
Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings results on Friday, November 9th. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.03). Neos Therapeutics had a negative net margin of 133.46% and a negative return on equity of 586.25%. The business had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $14.80 million. Sell-side analysts anticipate that Neos Therapeutics Inc will post -1.71 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. Allianz Asset Management GmbH purchased a new position in shares of Neos Therapeutics in the 1st quarter valued at about $161,000. Trexquant Investment LP acquired a new stake in Neos Therapeutics in the 2nd quarter worth about $131,000. Schwab Charles Investment Management Inc. boosted its holdings in Neos Therapeutics by 28.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 56,200 shares of the company’s stock worth $352,000 after buying an additional 12,500 shares during the last quarter. Millennium Management LLC acquired a new stake in Neos Therapeutics in the 1st quarter worth about $519,000. Finally, Canada Pension Plan Investment Board acquired a new stake in Neos Therapeutics in the 2nd quarter worth about $469,000. Hedge funds and other institutional investors own 45.12% of the company’s stock.
A number of equities analysts have weighed in on NEOS shares. Zacks Investment Research upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 11th. ValuEngine upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 18th. Cantor Fitzgerald restated a “buy” rating and issued a $20.00 price target on shares of Neos Therapeutics in a research note on Friday, November 9th. JMP Securities cut their price target on Neos Therapeutics from $22.00 to $10.00 and set a “market outperform” rating for the company in a research note on Monday, November 12th. Finally, Wells Fargo & Co cut their price target on Neos Therapeutics from $11.00 to $6.00 and set an “outperform” rating for the company in a research note on Wednesday, November 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $12.00.
ILLEGAL ACTIVITY NOTICE: “Neos Therapeutics Inc (NEOS) CEO Gerald W. Mclaughlin Buys 7,403 Shares of Stock” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://transcriptdaily.com/2018/12/08/neos-therapeutics-inc-neos-ceo-gerald-w-mclaughlin-buys-7403-shares-of-stock.html.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Read More: What are different types of coverage ratios?
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.